Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)
June 10, 2024 8:58 AM EDTBrookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $310.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Todays announcement for positive phase III data for mRNA-1083, its combination flu + COVID-19 vaccine candidate, supports our outlook. Combination vaccines have the... More
Morgan Stanley Reiterates Equalweight Rating on Moderna (MRNA)
June 10, 2024 6:52 AM EDTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $95.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "This morning MRNA announced that its Ph3 trial of mRNA-1083 (combo vaccine against influenza and COVID-19) has met its primary endpoints (LINK). We view this as an incremental positive for the stock as it could help bolster the tail of the COVID franchise, but we await further insight on the regulatory path. The ongoing Ph3 trial evaluated mRNA-1083 in two separate age groups of ~4,000 adults each. One consisted of adults 65 years and older,... More
Jefferies on Moderna (MRNA): 'Phase III Flu/Covid Combo looks good - could be on market in 2025'
June 10, 2024 6:52 AM EDTJefferies analyst Michael Yee reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Phase III data from MRNA's Covid+Flu combo vaccine today generally looks in-line with expectations and shows superior level of antibody titers in... More
